Genetic determinants of warfarin dosing in the Han-Chinese population.
about
Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysisPharmacogenomics and personalized medicine: a review focused on their application in the Chinese populationEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsWarfarin Pharmacogenetics: New Life for an Old DrugGenetic factors associated with patient-specific warfarin dose in ethnic IndonesiansGastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcomePharmacogenetics of warfarin: challenges and opportunities.Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analysesWarfarin dosage response related pharmacogenetics in Chinese population.Genetic warfarin dosing: tables versus algorithms.Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysisRole of pharmacogenomics in the management of traditional and novel oral anticoagulantsImpact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysisAssociation of genetic polymorphisms with warfarin dose requirements in Chinese patients.Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial.Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacementThe pharmacogenetics of the response to warfarin in Chinese.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patientsValidation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population.Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis.Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.Replication study of CYP4F2 association with warfarin response in an Israeli population.Prothrombotic SERPINC1 gene polymorphism may affect heparin sensitivity among different ethnicities of Chinese patients receiving heart surgery.Effect of gene polymorphims on the warfarin treatment at initial stage.Gamma-glutamyl carboxylase and its influence on warfarin dose.Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement
P2860
Q28071310-21F8D5E1-BCD2-484A-BA54-1AAB2922BC7DQ28083875-94AA6FE8-FCD2-4893-B185-FE9B423FEDF1Q28276514-12BB9BD8-2D9D-448C-A884-7B14C4B4425CQ28395337-64078AC4-70E7-4B88-9812-10F4C8DEB0DBQ28468726-0B085C55-3EC7-499F-B08F-F8433574A57FQ31016306-2DD26AF8-228F-4397-BF35-A61F26A86C7FQ33760056-7BFC6C56-C004-4FC0-AFAD-6085A245ADA5Q33819050-EFAEE64C-C9D5-4EB8-A8E3-520B98092967Q34078825-A636CE9E-C507-403B-B120-41DFCDF767B5Q34977531-6CBED7EC-8FDB-4655-9C38-C87A2EAEC5E5Q35021027-C205DD0D-635B-45A7-B3D0-2614B2111901Q35795269-7716FFF6-1E91-4A5D-B1DE-020B8A766930Q36368040-2C71B096-8519-4819-846C-426DBA5B76F6Q36742224-143481FC-F414-4D50-9AC0-C4EB3AD0293EQ36848449-737EEEC2-4994-4B49-A791-489663317FC6Q37065161-E6984EF1-AF2E-459A-8FF4-70E8ABCC11ADQ37398193-43F94915-851A-4D14-BD0A-6037437AE6C2Q37398898-7A780A4D-F8CB-413F-9927-0F275A563B8DQ37606335-5DF9203B-A795-45C8-867F-27E6CFB51BD2Q37948863-A24E49B2-6386-49B7-A02F-E7169EFF3FA5Q38078754-AF243090-4D65-47B5-8B4C-7BE50742F84BQ38760559-247BF9B5-4185-4D20-888B-4E3F664ECB23Q38897904-370577BE-B459-409F-A55B-787C8F3A15FBQ39096673-E99000C0-80B1-4BD7-9832-48293C4CEB54Q39471514-BE4C6662-489E-4F3E-B2DF-1E27524912EFQ39537454-FC43D100-F56F-407B-B348-5435EF700310Q41824237-993926BB-86BE-41E0-B956-0703C0BB6BE9Q42713959-CCEAE94B-F168-4A75-B055-6B077FFC0FEFQ42718669-AD2C73A8-5576-46EA-B21F-3C29CCD8E96BQ42722817-5A0CE935-E77D-4950-9806-557C2D03ACB0Q42791847-DD002676-08E6-4532-A558-345D1935CAEBQ42910090-DE10E65D-8C42-46A2-8350-3948EE9B056AQ44498037-E84EA6AB-D943-446F-B36C-081F12D310ABQ44865332-5B16E76F-2327-43B4-844A-BDA4AD0EB48AQ47834832-9BC84160-3C8D-4A42-9E07-CA2CF0C2D84EQ48905886-A2E6DE9D-4264-4AD3-B4BC-7DD92DD15CFDQ49811574-373974F1-F2F8-4A11-B4B3-41FCF6A72FCFQ53123110-513E1AD6-1A38-47D3-BCCF-372A593A8A27Q53268012-337B70A7-FE38-4939-97ED-C5CF18608279Q57500191-D875A486-4E8C-4F4A-B7A7-1E4E2C8C8517
P2860
Genetic determinants of warfarin dosing in the Han-Chinese population.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Genetic determinants of warfarin dosing in the Han-Chinese population.
@en
Genetic determinants of warfarin dosing in the Han-Chinese population.
@nl
type
label
Genetic determinants of warfarin dosing in the Han-Chinese population.
@en
Genetic determinants of warfarin dosing in the Han-Chinese population.
@nl
prefLabel
Genetic determinants of warfarin dosing in the Han-Chinese population.
@en
Genetic determinants of warfarin dosing in the Han-Chinese population.
@nl
P2093
P2860
P356
P1433
P1476
Genetic determinants of warfarin dosing in the Han-Chinese population.
@en
P2093
Amir N Saleem
Chien-Hsiun Chen
Ching-Heng Chou
Hui-Ping Chuang
Jer-Yuarn Wu
Jin-Jer Chen
Liang-Suei Lu
M T Michael Lee
Ming-Shien Wen
Ying-Ting Chen
P2860
P304
P356
10.2217/PGS.09.106
P577
2009-12-01T00:00:00Z